Updated: EQRx abandons its mission of drug price reform, will cut more than half of employees
EQRx’s plan to upend the US drug price system with lower-cost treatments is over.
On Monday, it announced a massive strategic reset, slashing its pipeline down to one drug and letting go approximately half its staff.
“We tried to change the system; maybe that was a stretch,” founder and EQRx executive chair Alexis Borisy told Endpoints News in an interview. “It was certainly a bold thing to try to go do, and it wasn’t to be.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.